A case report describes a 26-year-old man with relapsed/refractory classical Hodgkin lymphoma (cHL) who had already undergone an autologous stem cell transplant. After standard treatments failed, he received a combination of venetoclax, chidamide, and decitabine (Ven-Chi-Dec regimen).
Remarkably, after six cycles of this therapy, the patient achieved complete metabolic remission, meaning no signs of active cancer were detected on imaging. Importantly, he experienced no significant adverse effects during treatment.
This is only a single case report, so results cannot be generalized. The findings suggest that the Ven-Chi-Dec regimen might be a potential option for patients with relapsed cHL who have limited alternatives. However, larger studies are needed to confirm safety and effectiveness.
Doctors should consider this as preliminary evidence. The patient's positive outcome is encouraging but does not prove the regimen works for everyone. Further research is essential before this approach can be recommended broadly.